Nature Study Retools Human AGO2 Into ALTER, A C-to-U RNA Editor That Tops Cas13 Comparators In HEK293T Cells
The Catalyst Brief
Coverage
Biotech Innovation
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Latest
AbbVie Posts 30.2% Endoscopic Remission For ABBV-466, Topping Skyrizi Alone In Midphase Crohn’s Trial
The Catalyst Brief
Gilead Posts Phase 2 Emvistegrast Win In Ulcerative Colitis, Setting Up A 2027 Phase 3 Monotherapy Study
The Catalyst Brief
Nouscom Raises $135 Million For NOUS-209, Backing A Registration-Enabling Lynch Syndrome Trial
The Catalyst Brief
Most read
Osivax Shifts OVX836 To Combination Strategy After Phase 2b Miss In 2,850 Adults
The Catalyst Brief
Vanda Puts VQW-765 On Hold After Phase 3 Miss In Social Anxiety Disorder
The Catalyst Brief
Oct 17, 2026
STAT Spotlights Elizabeth Holmes Documentary As Theranos Coverage Returns To View
The Catalyst Brief
Nature Papers Detail Two Prime Editing Routes For Large DNA Insertions Without Double-Strand Breaks
The Catalyst Brief
More in this beat
STAT Spotlights Elizabeth Holmes Documentary As Theranos Coverage Returns To View
STAT used the release of “You Can See Everything” to point readers back to years of reporting on Elizabeth Holmes and Theranos. For biotech, the signal is that credibility failures do not end with a verdict; they remain part of how investors, scientists, and the public assess future diagnostic claims.
The Catalyst Brief
Oct 15, 2026Osivax Shifts OVX836 To Combination Strategy After Phase 2b Miss In 2,850 Adults
Osivax tested OVX836, a nucleoprotein-targeting influenza A vaccine, in 2,850 healthy adults in Europe and reported vaccine efficacy of 24%, below the 50% needed for the primary endpoint. The company is now prioritizing programs that combine OVX836 with licensed or partner seasonal flu vaccines, arguing that broader cellular immunity may add to strain-specific antibody protection rather than replace it.
The Catalyst Brief
Oct 15, 2026Vanda Puts VQW-765 On Hold After Phase 3 Miss In Social Anxiety Disorder
The phase 3 trial randomized 546 adults to a single oral dose of VQW-765 or placebo before a psychosocial stress test. Vanda had narrowed its primary analysis to women based on phase 2 data, but the company said the failure to replicate that signal will put the program on hold pending further analysis of the full dataset.
The Catalyst Brief
Oct 15, 2026Verastem Advances VS-7375 After Early KRAS G12D Data In Pancreatic And Lung Tumors
Verastem Oncology reported initial data from a phase 1/2 trial of VS-7375, its oral selective KRAS G12D inhibitor, across advanced solid tumors including metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer. The company now plans to start a phase 3 study by the end of the year, evaluating the drug alone and in combinations.
The Catalyst Brief
Oct 12, 2026Tortugas Highlights Obuprazine Phase 2b Win In 363 Patients, Backing U.S. Schizophrenia Plan
Obuprazine, also known as TRTL-107, is a D2/D3 partial agonist and 5-HT2A antagonist licensed from Hansoh. Tortugas now plans to seek FDA clearance to run a U.S. trial, using the China study as validation of both the molecule and the company's broader development model.
The Catalyst Brief
Oct 12, 2026Merck’s Remigromig Data Show Higher PDR Rates And Weaker BCVA Gains, Complicating Its DME Bet
Merck paid $1.3 billion upfront in 2024 to acquire the asset and the rest of Eyebiotech. The latest data shift the story from headline noninferiority to whether a new mechanism can compete if efficacy looks undifferentiated and safety appears less favorable than established anti-VEGF therapy.
The Catalyst Brief
Oct 9, 2026Endeavor Posts Phase 2b Taladegib Win In 213 IPF Patients, Setting Up FDA Phase 3 Talks
Endeavor BioMedicines said its phase 2b WHISTLE-PF study met its primary endpoint in 213 patients with idiopathic pulmonary fibrosis. Beyond lung function, the company said taladegib also showed significant improvement versus placebo on biomarkers including total lung capacity, quantitative total interstitial lung disease and quantitative lung fibrosis.
The Catalyst Brief
Oct 8, 2026Atsena Reports Lighthouse Responses For ATSN-201, Setting Up A 2028 XLRS Filing Plan
The readout comes from the first two parts of the phase 1/2/3 Lighthouse study, where 18 patients were treated in one eye and three served as untreated controls. For a disease with no approved, disease-specific treatments, the result gives Atsena a clearer argument for carrying its lowest dose into the registrational stage.
The Catalyst Brief
Oct 7, 2026Cerevance Revives Solengepras With Phase 3 Parkinson’s Win, After Last Year’s Midstage Miss
Cerevance reported that 150 mg solengepras, given once daily as an adjunct to levodopa, significantly reduced average daily OFF time versus placebo at Week 12 and showed improvements as early as Week 2. For a program that stumbled in untreated patients last year, the phase 3 result changes the strategic question from whether the mechanism works to how far a non-dopaminergic adjunct can differentiate in a crowded Parkinson’s market.
The Catalyst Brief
Oct 7, 2026MimiVax Misses Phase 2 Glioblastoma Goal With SurVaxM, But Points To Benefit In Younger Subset
In 233 evaluable patients, SurVaxM was associated with median overall survival of 24.2 months versus 20.2 months for placebo, but MimiVax said the trial still missed its primary endpoint. The company is focusing on a younger subset that it described as showing a significant benefit, including a progression-free survival difference at 12 months.
The Catalyst Brief
Oct 7, 2026Nuvig Halts NVG-2089 CIDP Trial, Keeping Midstage ITP Study Running
Nuvig has narrowed the path for its only clinical asset by ending one of two midstage studies. The move shifts attention to whether NVG-2089 can still find a viable development route through immune thrombocytopenia or another future indication.
The Catalyst Brief
Oct 7, 2026ArriVent Misses Phase 3 PFS Goal For Firmonertinib In 398-Patient NSCLC Trial, Sending Shares Down 57%
The study tested two doses of firmonertinib against platinum-based chemotherapy in 398 patients with non-squamous, locally advanced or metastatic non-small cell lung cancer. While the high dose improved response rate and showed stronger investigator-assessed PFS, the prespecified primary readout by BICR fell short.
The Catalyst Brief
Other beats
AI in Drug Discovery
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Biopharmaceutical Industry
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Healthcare Investment
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Medical Technology
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Regulatory & Policy
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.